Schisandrin A protects against isoproterenol‑induced chronic heart failure via miR‑155

Gao, Lijing; T, Li; Li, Shufen; Zhang, Song; Chang, Yongli; Li, Yuan

doi:10.3892/mmr.2021.12540

Cited by 11 publications

(4 citation statements)

References 54 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Enlargement/hypertrophy at the organ level is often assessed relative to denominators such as body weight or, particularly in mice, tibia length ( Gao et al, 2022 ). For instance, the latter is standard when exploring cardiac hypertrophy in disease and upon treatment in mice ( Dewenter et al, 2017 ; Tomimatsu et al, 2022 ).…”

Section: Discussionmentioning

confidence: 99%

A comparison of urinary bladder weight in male and female mice across five models of diabetes and obesity

et al. 2023

View full text Add to dashboard Cite

Introduction: Diabetes often leads to lower urinary tract dysfunction. The most frequently assessed parameter of urinary bladder dysfunction in animal models of diabetes is an enlargement of the bladder, which is consistently observed in type 1 and less consistently in type 2 diabetes. The vast majority of studies on bladder weight in animal models of diabetes and obesity has been performed in males, and no studies have directly compared this outcome parameter between sexes.Methods: Therefore, we have compared bladder weight and bladder/body weight ratio in five mouse models of obesity and diabetes (RIP-LCMV, db/db, ob/ob (two studies), insulin receptor substrate 2 (IRS2) knock-out mice and mice on a high-fat diet; pre-specified secondary analysis of a previously reported study).Results: In a pooled analysis of the control groups of all studies, females exhibited slightly lower glucose levels, lower body weight, and lower bladder weight, but bladder/body weight ratio was similar in both sexes (0.957 vs. 0.986 mg/g, mean difference 0.029 [−0.06; 0.118]). Among the six diabetic/obese groups, bladder/body weight ratio was similar in both sexes in three but smaller in female mice in three other groups. The mRNA expression of a panel of genes implied in the pathophysiology of bladder enlargement and/or fibrosis and inflammation did not differ systematically between sexes.Conclusions: We conclude that sex differences in diabetes/obesity-associated bladder enlargement may be model dependent.

show abstract

Section: Discussionmentioning

confidence: 99%

A comparison of urinary bladder weight in male and female mice across five models of diabetes and obesity

et al. 2023

View full text Add to dashboard Cite

show abstract

“…Propranolol, a non-selective β-AR antagonist, was administered in the drinking water at a concentration of 0.5 g/L. The doses and routes of administration of these drugs were those used in previous studies (Gao et al, 2022;Maruyama et al, 2018;Muehleman et al, 2022;Te Riet et al, 2016;Turner et al, 2020;Walsh-Wilkinson et al, 2021). The body mass and water intake of the mice were measured daily.…”

Section: Experimental Protocolmentioning

confidence: 99%

Chronic activation of β-adrenergic receptors leads to tissue water and electrolyte retention

Akumwami,

Kitada,

Fujisawa

et al. 2024

J Pharmacol Exp Ther

View full text Add to dashboard Cite

Beta-adrenergic receptors (β-AR) are expressed on the membranes of various cell types and their activation affects body water balance by modulating renal sodium and water excretion, cardiovascular function and metabolic processes. However, β-AR-associated body fluid imbalance has not been well characterised. In the present study, we hypothesized that chronic β-AR stimulation increases electrolyte and water content at the tissue level. We evaluated the effects of isoproterenol, a non-selective β-AR agonist, on electrolyte and water balance at the tissue level. Continuous isoproterenol administration for 14 days induced cardiac hypertrophy, associated with sodium-driven water retention in the heart, increased the total body sodium, potassium and water contents at the tissue level, and increased the water intake and blood pressure of the mice. There was greater urine output in response to the isoproterenol-induced body water retention. These isoproterenol-induced changes were reduced by propranolol, a nonselective beta-receptor inhibitor. Isoproterenol-treated mice even without excessive water intake had higher total body electrolyte and water contents, and this tissue water retention was associated with lower dry body mass, suggesting that β-AR stimulation in the absence of excess water intake induces catabolism and water retention. These findings suggest that β-AR activation induces tissue sodium and potassium retention, leading to body fluid retention, with or without excess water intake. This characterisation of β-AR-induced electrolyte and fluid abnormalities improves our understanding of the pharmacological effects of β-AR inhibitors.

show abstract

“…Then, miR-30c-5p is associated with pyroptosis repression, which can lead to AS ( 94 ). Schisandrin A has been studied for its protective role in chronic heart failure via the upregulation of miR-155, which represses the necroptosis of cardiomyocytes ( 152 ). Moreover, we found that nicorandil combined with trimetazidine treatment can attenuate the progress of CHD via upregulating the miR-223-3p ( 153 ).…”

Section: Ncrnas As Therapeutic Targets In Cvdsmentioning

confidence: 99%

Non-coding RNAs in necroptosis, pyroptosis, and ferroptosis in cardiovascular diseases

Cai

Zhou

et al. 2022

Front. Cardiovasc. Med.

View full text Add to dashboard Cite

Accumulating evidence has proved that non-coding RNAs (ncRNAs) play a critical role in the genetic programming and gene regulation of cardiovascular diseases (CVDs). Cardiovascular disease morbidity and mortality are rising and have become a primary public health issue that requires immediate resolution through effective intervention. Numerous studies have revealed that new types of cell death, such as pyroptosis, necroptosis, and ferroptosis, play critical cellular roles in CVD progression. It is worth noting that ncRNAs are critical novel regulators of cardiovascular risk factors and cell functions by mediating pyroptosis, necroptosis, and ferroptosis. Thus, ncRNAs can be regarded as promising therapeutic targets for treating and diagnosing cardiovascular diseases. Recently, there has been a surge of interest in the mediation of ncRNAs on three types of cell death in regulating tissue homeostasis and pathophysiological conditions in CVDs. Although our understanding of ncRNAs remains in its infancy, the studies reviewed here may provide important new insights into how ncRNAs interact with CVDs. This review summarizes what is known about the functions of ncRNAs in modulating cell death-associated CVDs and their role in CVDs, as well as their current limitations and future prospects.

show abstract

Schisandrin A protects against isoproterenol‑induced chronic heart failure via miR‑155

Cited by 11 publications

References 54 publications

A comparison of urinary bladder weight in male and female mice across five models of diabetes and obesity

A comparison of urinary bladder weight in male and female mice across five models of diabetes and obesity

Chronic activation of β-adrenergic receptors leads to tissue water and electrolyte retention

Non-coding RNAs in necroptosis, pyroptosis, and ferroptosis in cardiovascular diseases

Contact Info

Product

Resources

About